JP5656857B2 - ペプチドアジュバント - Google Patents

ペプチドアジュバント Download PDF

Info

Publication number
JP5656857B2
JP5656857B2 JP2011537804A JP2011537804A JP5656857B2 JP 5656857 B2 JP5656857 B2 JP 5656857B2 JP 2011537804 A JP2011537804 A JP 2011537804A JP 2011537804 A JP2011537804 A JP 2011537804A JP 5656857 B2 JP5656857 B2 JP 5656857B2
Authority
JP
Japan
Prior art keywords
seq
peptide
antigen
adjuvant
pentamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011537804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509906A5 (enExample
JP2012509906A (ja
Inventor
パーテル，アミ
コバサ，ダーウイン
コビンジャー，ゲイリー
バビウク，ショーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canada, Represented By Minister Of Health AS
Health Canada
Original Assignee
Canada, Represented By Minister Of Health AS
Health Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canada, Represented By Minister Of Health AS, Health Canada filed Critical Canada, Represented By Minister Of Health AS
Publication of JP2012509906A publication Critical patent/JP2012509906A/ja
Publication of JP2012509906A5 publication Critical patent/JP2012509906A5/ja
Application granted granted Critical
Publication of JP5656857B2 publication Critical patent/JP5656857B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011537804A 2008-11-28 2009-11-30 ペプチドアジュバント Expired - Fee Related JP5656857B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11853308P 2008-11-28 2008-11-28
US61/118,533 2008-11-28
PCT/CA2009/001707 WO2010060208A1 (en) 2008-11-28 2009-11-30 Peptide adjuvants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014237037A Division JP5901084B2 (ja) 2008-11-28 2014-11-21 ペプチドアジュバント

Publications (3)

Publication Number Publication Date
JP2012509906A JP2012509906A (ja) 2012-04-26
JP2012509906A5 JP2012509906A5 (enExample) 2014-06-26
JP5656857B2 true JP5656857B2 (ja) 2015-01-21

Family

ID=42225170

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011537804A Expired - Fee Related JP5656857B2 (ja) 2008-11-28 2009-11-30 ペプチドアジュバント
JP2014237037A Expired - Fee Related JP5901084B2 (ja) 2008-11-28 2014-11-21 ペプチドアジュバント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014237037A Expired - Fee Related JP5901084B2 (ja) 2008-11-28 2014-11-21 ペプチドアジュバント

Country Status (8)

Country Link
US (2) US8404243B2 (enExample)
EP (2) EP2987502B1 (enExample)
JP (2) JP5656857B2 (enExample)
AU (2) AU2009319667B2 (enExample)
CA (1) CA2740566C (enExample)
ES (2) ES2615120T3 (enExample)
NZ (1) NZ593200A (enExample)
WO (1) WO2010060208A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012153337A2 (en) * 2011-05-11 2012-11-15 Technion Research & Development Foundation Ltd. Anti-microbial peptides and uses of same
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
CA3100236A1 (en) * 2020-11-20 2022-05-20 Universite Laval Severe acute respiratory syndrome coronavirus dna vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
GB9425582D0 (en) * 1994-12-19 1995-02-15 Iaf Biochem Int Peptides having immunomodulatory activity
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US7371837B2 (en) * 2004-07-21 2008-05-13 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof

Also Published As

Publication number Publication date
US9211325B2 (en) 2015-12-15
EP2370100B1 (en) 2015-04-08
US8404243B2 (en) 2013-03-26
AU2016201589B2 (en) 2016-11-24
AU2016201589A1 (en) 2016-03-31
WO2010060208A1 (en) 2010-06-03
AU2009319667A1 (en) 2011-06-23
EP2370100A4 (en) 2013-05-22
EP2370100A1 (en) 2011-10-05
CA2740566C (en) 2017-11-28
JP2012509906A (ja) 2012-04-26
JP5901084B2 (ja) 2016-04-06
US20130323285A1 (en) 2013-12-05
EP2987502B1 (en) 2016-11-09
US20110305720A1 (en) 2011-12-15
CA2740566A1 (en) 2010-06-03
ES2541443T3 (es) 2015-07-20
JP2015091811A (ja) 2015-05-14
EP2987502A1 (en) 2016-02-24
AU2009319667B2 (en) 2016-03-03
NZ593200A (en) 2012-10-26
ES2615120T3 (es) 2017-06-05

Similar Documents

Publication Publication Date Title
AU692152B2 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
JP5654345B2 (ja) 多量体マルチエピトープインフルエンザワクチン
TW202039587A (zh) 供合成胜肽免疫原作為免疫刺激劑的人工混雜t輔助細胞抗原決定位
JP2024095743A (ja) 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ
JP2010506926A (ja) Ｉｉ−Ｋｅｙ増強ワクチンの効力
JP5901084B2 (ja) ペプチドアジュバント
Yoon et al. Comparison of responses elicited by immunization with a Legionella species common lipoprotein delivered as naked DNA or recombinant protein
CN113476600B (zh) Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物
WO2012114323A1 (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
AU2018371355B2 (en) Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV)
Arnon et al. Peptide-based synthetic recombinant vaccines with anti-viral efficacy
WO2018085488A1 (en) Universal mammalian influenza vaccine
WO2012040266A2 (en) Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
CN121342933A (zh) 冠状病毒s蛋白突变体及其应用
JP2024540322A (ja) ＳＡＲＳ－ＣｏＶ－２によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン
US20030228327A1 (en) DNA-based plasmid formulations and vaccines and prophylactics containing the same
BERGER et al. o. 3 Vaccination strategy to treat persistent viral infections
Mažeikė Generation of anticancer vaccine based on virus-like particles
HK1192455A (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140127

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141125

R150 Certificate of patent or registration of utility model

Ref document number: 5656857

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees